Preoperative Radiotherapy Remains Standard of Care for Soft Tissue Sarcoma, New ESTRO-ASTRO Guideline Confirms

Why It Matters

By prioritizing preoperative radiotherapy, the guideline reduces late‑toxicity while preserving oncologic outcomes, shaping standards for multidisciplinary sarcoma care. It also signals where future research and investment—immunotherapy integration and hypofractionation—will focus.

Key Takeaways

• Preoperative RT (50–50.4 Gy) remains preferred over postoperative approach.
• Post‑operative boost after preop RT is not recommended, even with R1 margins.
• Myxoid liposarcoma may be treated with investigational 36 Gy preop dose.
• Immunotherapy plus preop RT shows disease‑free survival benefit in phase 2 trial.
• Hypofractionated regimens remain experimental pending head‑to‑head toxicity data.

Pulse Analysis

Soft‑tissue sarcoma (STS) remains a therapeutic challenge due to its heterogeneity and propensity for local recurrence. The new ESTRO‑ASTRO guideline consolidates a decade of evidence, confirming that preoperative, conventionally fractionated radiotherapy—delivered at 50–50.4 Gy in 1.8–2 Gy fractions—offers comparable tumor control to postoperative approaches while markedly lowering rates of fibrosis, lymphedema, and joint stiffness. By standardizing dose and eliminating routine postoperative boosts, the guideline simplifies treatment planning and reduces cumulative radiation exposure, a critical consideration for limb‑sparing surgery.

Beyond reaffirming established practice, the guideline introduces nuanced, subtype‑specific recommendations. Myxoid liposarcoma, recognized for heightened radiosensitivity, may be managed with an investigational 36 Gy regimen, potentially shortening treatment duration without compromising efficacy. For myxofibrosarcoma, wider clinical target volumes are advised to account for its infiltrative growth pattern. The document also acknowledges early signals from the SU2C‑SARC032 phase 2 trial, where adding pembrolizumab to preoperative RT improved disease‑free survival in high‑grade undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, hinting at a future immunoradiotherapy paradigm.

Clinicians and health‑system leaders should view the guideline as both a reaffirmation of best‑practice radiotherapy and a roadmap for emerging therapies. Multidisciplinary sarcoma centers will need to integrate immunotherapy trials and rigorously evaluate hypofractionated schedules as data mature. Investment in advanced imaging, adaptive planning, and collaborative research networks will be essential to translate these recommendations into improved patient outcomes and sustainable oncology practice.